International Stem Cell Corp. (ISCO.OB) to Conduct Experiments to Get Clear View of Age-Related Macular Degeneration
QualityStocks (March 18th, 2010) Writes:
Biotechnology company International Stem Cell Corporation today announced that its Research and Therapeutic Development Group will team up with scientists from the University of California, Irvine to conduct a second phase of preclinical experiments on retinal pigment epithelium (RPE), (in layman’s terms, the colored cell layer of the retina), derived from parthenogenetic stem cells.
RPE is an integral part of proper eye function. The loss of function contributes to a variety of disabling eye conditions, including age-related macular degeneration (AMD), the leading cause of vision loss in seniors.
ISCO’s preclinical research will allow scientists to test the restoration ability of the cells affected by retinal degeneration in rodent models. The company said that previous data on animal models showed “encouraging” results, demonstrating that visual degradation caused by AMD can be slowed through RPE transplantation.
In the past, one of the major barriers for transplantation is the lack of sufficient RPE cells
...

![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)






